Pfizer and BioNTech Start Clinical Trials of Omicron Special Covid-19 Vaccine

Two pharmaceutical companies, Pfizer and BioNTech, have conducted clinical trials for the Omicron variant of the Covid-19 vaccine candidate. The study was conducted to evaluate the safety, tolerability, and level of immune response of the vaccine.

Both as main and booster doses, which were administered to 1,420 healthy adults aged 18 to 55 years. The study was divided into three groups based on the history of receiving their respective vaccines.

The Omicron vaccine will be given in 30 micrograms, the same as the current dose. This production process is considered necessary to provide a high level of protection against severe illness and hospitalization due to this latest Covid-19 mutation.

"We recognize the need to be prepared as this protection wears off over time and could potentially help address Omicron and new variants in the future," said Senior Vice

President and Head of Vaccine Research and Development Kathrin Jansen, quoted from CNN. Previously, Pfizer was expected to launch a special Omicron vaccine product in March, according to the company's CEO, Albert Bourla.

But production started early according to this latest statement from the US pharmaceutical company. "After Omicron, we are proactively investigating and manufacturing risky Omicron-based vaccines if needed," said a Pfizer spokesperson.

However, this health product still needs a sound scientific basis and the results of discussions with health authorities and approval before it will be used Pfizer previously planned to produce four billion doses of Pfizer-BioNTech COVID-19 Vaccine by 2022.

This number is not expected to change if the Omicron vaccine has been successfully created. People who have received the booster vaccine are also said to still have a high level of protection against Omicron, especially against the risk of severe illness and hospitalization.

Weergaven: 8

Hierop reageren

© 2022   Gemaakt door Beter HBO.   Verzorgd door

Banners  |  Een probleem rapporteren?  |  Algemene voorwaarden